IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8+ T cells

Journal of Immunology

Volumn 173, Issue 12, 2004, Pages 7170-7182

  Salcedo, Rosalba ^a   Stauffer, Jimmy K ^a   Lincoln, Erin ^b   Back, Timothy C ^b   Hixon, Julie A ^a   Hahn, Cynthia ^a   Shafer Weaver, Kimberly ^b   Malyguine, Anatoli ^b   Kastelein, Robert ^c   Wigginton, Jon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 27; INTERLEUKIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; METASTASIS; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR MODEL; TUMOR REGRESSION;

EID: 10344228778     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.12.7170     Document Type: Article

References (69)

1. Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, et al. 1996. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli and studies on the biologic activities of the protein. J. Immunol. 156:4274.
2. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. Emphasis Tumor Immunol. 17:71.
3. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, and K. Hattori. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88.
4. Tominaga, K., T. Yoshimoto, K. Torigoe, M. Kurimoto, K. Matsui, T. Hada, H. Okamura, and K. Nakanishi. 2000. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int. Immunol. 12:151.
5. Tan, J., B. E. Crucian, A. E. Chang, E. Aruga, A. Aruga, S. E. Dovhey, K. Tanigawa, and H. Yu. 1998. Interferon-γ-inducing factor elicits antitumor immunity in association with interferon-γ production. J. Immunol. 21:48.
6. Yu, W. G., M. Ogawa, J. Mu, K. Umehara, T. Tsujimura, H. Fujiwara, and T. Hamaoka. 1997. IL-12-induced tumor regression correlates with in situ activity of IFN-γ produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J. Leukocyte Biol. 62:450.
7. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
8. Wigginton, J. M., and R. H. Wiltrout. 2002. IL-12/IL-2 combination cytokine therapy for solid tumors: translation from bench to bedside. Expert Opin. Biol. Ther. 2:513.
9. Wigginton, J. M., K. L. Komschlies, T. C. Back, J. L. Franco, M. J. Brunda, and R. H. Wiltrout. 1996. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88:38.
10. Wigginton, J. M., J. K. Lee, T. A. Wiltrout, W. G. Alvord, J. A. Hixon, J. Subleski, T. C. Back, and R. H. Wiltrout. 2002. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J. Immunol. 169:4467.
11. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6:1678.
12. Lee, P., F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, C. Gee, R. Lau, G. Jeffery, K. Margolin, et al. 2001. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:3836.
13. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715.
14. + T cells. Immunity 16:779.
15. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133.
16. Robinson, D. S., and A. O'Garra. 2002. Further checkpoints in Th1 development. Immunity 16:755.
17. Dinarello, C. A. 1999. Interleukin-18. Methods 19:121.
18. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168:5699.
19. Brombacher, F., R. A. Kastelein, and G. Alber. 2003. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24:207.
20. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744.
21. Lo, C. H., S. C. Lee, P. Y. Wu, W. Y. Pan, J. Su, C. W. Cheng, S. R. Roffler, B. L. Chiang, C. N. Lee, C. W. Wu, and M. H. Tao. 2003. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171:600.
22. Wang, Y. Q., S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa. 2003. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells, Int. J. Cancer 105:820.
23. Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, T. K. McClanahan, R. De Waal Malefyt, and R. A. Kastelein. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172:2225.
24. Chen, Q., N. Ghilardi, H. Wang, T. Baker, M. H. Xie, A. Gurney, I. S. Grewal, and F. J. de Sauvage. 2000. Development of Th1-type immune responses requires the type 1 cytokine receptor TCCR. Nature 407:916.
25. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170:4886.
26. Yoshida, H., S. Hamano, G. Senaldi, T. Covey, R. Faggioni, S. Mu, M. Xia, A. C. Wakeham, H. Nishina, J. Potter, et al. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15:569.
27. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445.
28. Hammerling, G. J., U. Hammerling, and L. Flaherty. 1979. Qat-4 and Qat-5, new murine T-cell antigens governed by the T1a region and identified by monoclonal antibodies. J. Exp. Med. 150:108.
29. Leo, O., D. H. Sachs, L. E. Samelson, M. Foo, R. Quinones, R. Gress, and J. A. Bluestone. 1986. Identification of monoclonal antibodies specific for the T cell receptor complex by Fc receptor-mediated CTL lysis. J. Immunol. 137:3874.
30. Rosenthal, M. A., D. Dennis, L. Liebes, P. Furmanski, D. Caron, L. Garrison, J. Wiprovnick, D. Peace, R. Oratz, J. Speyer, and A. Chachoua. 1998. Biologic activity of interleukin 1 (IL-1) α in patients with refractory malignancies. J. Immunother. 21:371.
31. Nemunaitis, J., F. R. Appelbaum, K. Lilleby, W. C. Buhles, C. Rosenfeld, Z. R. Zeigler, R. K. Shadduck, J. W. Singer, W. Meyer, and C. D. Buckner. 1994. Phase I study of recombinant interleukin-1β in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 83:3473.
32. Yang, J. C., R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, D. E. White, et al. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21:3127.
33. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:409.
34. Fyfe, G., R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, and A. C. Louie. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688.
35. Ghosh, A. K., N. K. Smith, J. Prendiville, N. Thatcher, D. Crowther, and P. L. Stern. 1993. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Eur. Cytokine Network 4:205.
36. Sosman, J. A., F. R. Aronson, M. Sznol, M. B. Atkins, J. P. Dutcher, G. R. Weiss, R. E. Isaacs, K. A. Margolin, R. I. Fisher, M. L. Ernest, et al. 1997. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin. Cancer Res. 3:39.
37. Motzer, R. J., A. Rakhit, L. H. Schwartz, T. Olencki, T. M. Malone, K. Sandstrom, R. Nadeau, H. Parmar, and R. Bukowski. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4:1183.
38. Schiller, J. H., M. Pugh, J. M. Kirkwood, D. Karp, M. Larson, and E. Borden. 1996. Eastern cooperative group trial of interferon γ in metastatic melanoma: an innovative study design. Clin. Cancer Res. 2:29.
39. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17:2105.
40. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869.
41. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, and W. J. Storkus. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
42. Nakamura, K., H. Okamura, M. Wada, K. Nagata, and T. Tamura. 1989. Endotoxin-induced serum factor that stimulates γ interferon production. Infect. Immun. 57:590.
43. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
44. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
45. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155.
46. Osaki, T., J. M. Peron, Q. Cai, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ and IL-12-independent antitumor effects. J. Immunol. 160:1742.
47. Hashimoto, W., T. Osaki, H. Okamura, P. D. Robbins, M. Kurimoto, S. Nagata, M. T. Lotze, and H. Tahara. 1999. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand. J. Immunol. 163:583.
48. Jonak, Z. L., S. Trulli, C. Maier, F. L. McCabe, R. Kirkpatrick, K. Johanson, Y. S. Ho, L. Elefante, Y. J. Chen, D. Herzyk, et al. 2002. High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J. Immunother. 25(Suppl. 1):S20.
49. Son, Y. I., R. M. Dallal, R. B. Mailliard, S. Egawa, Z. L. Jonak, and M. T. Lotze. 2001. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res. 61:884.
50. Son, Y. I., R. M. Dallal, and M. T. Lotze. 2003. Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J. Immunother. 26:234.
51. Gollob, J. A., K. G. Veenstra, R. A. Parker, J. W. Mier, D. F. McDermott, D. Clancy, L. Tutin, H. Koon, and M. B. Atkins. 2003. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21:2564.
52. Wigginton, J. M. 2003. A phase I investigation of dose-intensive intravenous IL-12/pulse IL-2 in adults with advanced solid tumors. J. Immunother. 23:S42.
53. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13:169.
54. Waldmann, T. A. 2003. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol. Med. 9:517.
55. Fry, T. J., and C. L. Mackall. 2002. Interleukin-7: from bench to clinic. Blood 99:3892.
56. Parrish-Novak, J., D. C. Foster, R. D. Holly, and C. H. Clegg. 2002. Interleukin-21 and the IL-21 receptor, novel effectors of NK and T cell responses. J. Leukocyte Biol. 72:856.
57. Gracie, J. A., S. E. Robertson, and I. B. McInnes. 2003. Interleukin-18. J. Leukocyte Biol. 73:213.
58. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12:53.
59. Cordoba-Rodriguez, R., and D. M. Frucht. 2003. IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin. Biot. Ther. 3:715.
60. Watford, W. T., M. Moriguchi, A. Morinobu, and J. J. O'Shea. 2003. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14:361.
61. Hisada, M., S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto. 2004. Potent antitumor activity of interleukin-27. Cancer Res. 64:1152.
62. Brodeur, G. M. 2003. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3:203.
63. Weinstein, J. L., H. M. Katzenstein, and S. L. Cohn. 2003. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8:278.
64. Wigginton, J. M., E. Grays, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108:51.
65. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 100:15047.
66. Hibbert, L., S. Pflanz, R. De Waal Malefyt, and R. A. Kastelein. 2003. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J. Interferon Cytokine Res. 23:513.
67. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581.
68. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877.
69. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.